AzTrials
AzTrials

OsteoporosisNCT07739628

Validation of a Deep Learning Tool for Opportunistic Osteoporosis Screening Using Routine Non-Contrast CT Scans

An observational study of Osteoporosis, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to test if an artificial intelligence (AI) tool called DeepBMD can accurately identify people at high risk for osteoporosis using routine chest or abdomen CT scans. The main questions it aims to answer are: 1. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Osteoporosis
What is being tested?
DeepBMD model for osteoporosis risk screening
How many people
100 participants
Where
1 siteChina
Study dates
28 Jul 2026to Sep 2026
How long will I take part?
7 Days
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients who underwent non-contrast CT at our hospital (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) and were identified as high-risk for osteoporosis by the DeepBMD model.

Who may be able to join

  • Underwent non-contrast CT at our institution, with qualified image quality and no severe artifacts;
  • Identified as high-risk for osteoporosis by the DeepBMD model;
  • Had valid contact information available in the PACS, possessed normal cognitive and communication abilities, and was able to cooperate with telephone follow-ups and on-site examinations;
  • Voluntarily participated in the study, was able to sign a written informed consent form on-site, and agreed to undergo DXA examination.

Who cannot join

  • Severe spinal deformity, postoperative spinal internal fixation, malignant bone metastasis, or severe osteolytic lesions that may interfere with measurements;
  • A confirmed diagnosis of osteoporosis with ongoing standardized treatment;
  • Inability to be contacted, explicit refusal of follow-up, or inability to visit the hospital for informed consent signing and DXA examination.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022

Other trials in China

About this study

Official title: Prospective Clinical Validation Study of a Deep Learning Model for Opportunistic Osteoporosis Screening Based on Non-Contrast CT Scans

The goal of this clinical trial is to test if an artificial intelligence (AI) tool called DeepBMD can accurately identify people at high risk for osteoporosis using routine chest or abdomen CT scans. The main questions it aims to answer are:

  1. Can the DeepBMD tool correctly identify people who have osteoporosis compared to the standard bone density test, dual-energy X-ray absorptiometry (DXA)?
  2. Is it practical to use this AI tool in real-world hospital settings to find and contact high-risk patients? Researchers will use the DeepBMD tool to analyze existing CT scans. If the tool flags a patient as high risk, researchers will call them to invite them for a standard bone density test (DXA).
Read more

Participants will:

  1. Have their existing chest or abdomen CT scan analyzed by the DeepBMD AI tool;
  2. Receive a phone call from the research team if identified as high risk;
  3. Visit the clinic for a free standard bone density test (DXA) if they agree to participate.
Conditions
Osteoporosis
Being tested
DeepBMD model for osteoporosis risk screening
Keywords
Osteoporosis, Opportunistic Screening, Deep Learning, Bone Mineral Density, Computed Tomography (CT)
Medical subject headings
Osteoporosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DeepBMD model for osteoporosis risk screeningDiagnostic test

    The DeepBMD model is applied to routine chest or abdominal CT scans to identify patients at high risk for osteoporosis. This is a non-invasive image analysis used solely for screening and recruitment purposes, not as a therapeutic intervention.

Study groups in NCT07739628
Study groupRoleWhat they receive
High-risk patients for osteoporosis identified by DeepBMD modelPatients who underwent routine chest or abdominal CT scans and were identified as high risk for osteoporosis by the DeepBMD AI model. These participants will be contacted via telephone, invited to the clinic, and undergo a free DXA scan to verify bone mineral density.
Receives: Diagnostic Test: DeepBMD model for osteoporosis risk screening

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic performance of DeepBMD model for osteoporosis screening

    The diagnostic performance of the DeepBMD model will be evaluated by comparing its predictions against the gold standard Dual-energy X-ray Absorptiometry (DXA). Specifically, we will calculate the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the Area Under the Receiver Operating Characteristic Curve (AUC) for identifying patients with osteoporosis.

    Measured: Concurrent with the DXA validation visit following the CT analysis (within 7 days).

Secondary outcomes (1)
  1. Feasibility of the DeepBMD screening and recall workflow

    It will be assessed by calculating the proportion of patients identified as high-risk by DeepBMD who successfully complete the telephone follow-up and undergo the confirmatory DXA scan within the scheduled timeframe. We will also record the reasons for refusal or loss to follow-up to evaluate the acceptability of this AI-driven screening pathway.

    Measured: At the end of recruitment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2026
  2. Study start28 Jul 2026
  3. Primary completion28 Aug 2026
  4. Study completionSep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
Target duration
7 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT07739628
Sponsor's protocol ID
UHCT260668
Status last verified
Sep 2026
First submitted
22 Jul 2026
Last updated
3 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data (IPD) will be made available to researchers who provide a methodologically sound proposal. The shared data will include the demographic information, DeepBMD screening results, and confirmatory DXA T-scores used in the study analyses. Requests should be directed to the corresponding author via email. Data will be available for non-commercial academic research purposes only. Applicants must sign a data access agreement prior to receiving the data.

Publications

  • Jang S, Graffy PM, Ziemlewicz TJ, Lee SJ, Summers RM, Pickhardt PJ. Opportunistic Osteoporosis Screening at Routine Abdominal and Thoracic CT: Normative L1 Trabecular Attenuation Values in More than 20 000 Adults. Radiology. 2019 May;291(2):360-367. doi: 10.1148/radiol.2019181648. Epub 2019 Mar 26.

    PubMed 30912719
  • Wang P, She W, Mao Z, Zhou X, Li Y, Niu J, Jiang M, Huang G. Use of routine computed tomography scans for detecting osteoporosis in thoracolumbar vertebral bodies. Skeletal Radiol. 2021 Feb;50(2):371-379. doi: 10.1007/s00256-020-03573-y. Epub 2020 Aug 7.

    PubMed 32767060
  • Smith AD. Screening of Bone Density at CT: An Overlooked Opportunity. Radiology. 2019 May;291(2):368-369. doi: 10.1148/radiol.2019190434. Epub 2019 Mar 26. No abstract available.

    PubMed 30917293
  • Zeng Q, Li N, Wang Q, Feng J, Sun D, Zhang Q, Huang J, Wen Q, Hu R, Wang L, Ma Y, Fu X, Dong S, Cheng X. The Prevalence of Osteoporosis in China, a Nationwide, Multicenter DXA Survey. J Bone Miner Res. 2019 Oct;34(10):1789-1797. doi: 10.1002/jbmr.3757. Epub 2019 Aug 29.

    PubMed 31067339
  • Cheng X, Zhao K, Zha X, Du X, Li Y, Chen S, Wu Y, Li S, Lu Y, Zhang Y, Xiao X, Li Y, Ma X, Gong X, Chen W, Yang Y, Jiao J, Chen B, Lv Y, Gao J, Hong G, Pan Y, Yan Y, Qi H, Ran L, Zhai J, Wang L, Li K, Fu H, Wu J, Liu S, Blake GM, Pickhardt PJ, Ma Y, Fu X, Dong S, Zeng Q, Guo Z, Hind K, Engelke K, Tian W; China Health Big Data (China Biobank) project investigators. Opportunistic Screening Using Low-Dose CT and the Prevalence of Osteoporosis in China: A Nationwide, Multicenter Study. J Bone Miner Res. 2021 Mar;36(3):427-435. doi: 10.1002/jbmr.4187. Epub 2020 Nov 4.

    PubMed 33145809
  • Lin X, Xiong D, Peng YQ, Sheng ZF, Wu XY, Wu XP, Wu F, Yuan LQ, Liao EY. Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives. Clin Interv Aging. 2015 Jun 25;10:1017-33. doi: 10.2147/CIA.S54613. eCollection 2015.

    PubMed 26150706

Questions about this trial

What is this clinical trial studying?

An observational study of Osteoporosis, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic performance of DeepBMD model for osteoporosis screening (time frame: Concurrent with the DXA validation visit following the CT analysis (within 7 days).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07739628, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in